The HIV sector responds to NICE’s draft decision to reject Cabotegravir (CAB-LA)
Last Updated:We are deeply disappointed by the decision not to recommend CAB-LA as an HIV prevention option.
We are deeply disappointed by the decision not to recommend CAB-LA as an HIV prevention option.
Urgent action is now needed to expand access to testing and reach people not in care